48-0458-42

antibody from Invitrogen Antibodies

Targeting: PTPRC CD45, GP180, LCA, T200

Provider product page for 48-0458-42

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [16]
Comments [0]
Validations
Flow cytometry [1]
Other assay [6]

Submit

Product number: 48-0458-42 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD45RA Monoclonal Antibody (HI100), eFluor™ 450, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The HI100 monoclonal antibody reacts with human CD45RA, a 220 kDa molecule expressed by subpopulations of CD4+ peripheral T lymphocytes, CD8+ peripheral T lymphocytes, and B cells. The CD45RA+ T cell populations are mainly naive/virgin allowing the use of HI100 mAb as a phenotypic marker to discriminate T cell subsets. Applications Reported: This HI100 antibody has been reported for use in flow cytometric analysis. Applications Tested: This HI100 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral mononuclear cells. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. eFluor® 450 is an alternative to Pacific Blue®. eFluor® 450 emits at 445 nm and is excited with the Violet laser (405 nm). Please make sure that your instrument is capable of detecting this fluorochome. Excitation: 405 nm; Emission: 445 nm; Laser: Violet Laser. Filtration: 0.2 µm post-manufacturing filtered.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: HI100
Vial size: 100 Tests
Concentration: 5 µL/Test
Storage: 4° C, store in dark, DO NOT FREEZE!

PTPRC protein structure - 48-0458-42 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 The distribution of CD4+ and CD8+ T cells subsets in human lung cancer. PBMCs were isolated from the blood of lung cancer patients and healthy donors and analyzed by flow cytometry. a The frequency of the CD3+CD4+ T cells and CD3+CD8+ T cells in the HD-PBMC, PBMCs from healthy donors; NSCLC-PBMC, PBMCs from non-small lung cancer patients, Normal-Ly, from healthy lymph node, NSCLC-Ly, tumor infiltrated lymph node from non-small lung cancer patients. b Representative flow cytometric analyses of CD45RA and CCR7 expression in CD3+CD4+ T cells and CD3+CD8+ T cells, indicating naive T cells (CD45RA+/CD45RO-CCR7+, top right quadrant ), terminal effector T cells (CD45RA+/CD45RO-CCR7-, bottom right quadrant ), central memory T cells (Tcm, CD45RO+/CD45RA-CCR7+, top left quadrant ), and effector memory T cells (Tem, CD45RO+/CD45RA-CCR7-, bottom left quadrant ), gated on the forward and side scatter of the lymphocyte populations. c The frequency and absolute number of the CD4+ ( top ) and CD8+ ( bottom ), Tn ( middle gray ), Teff ( black ), Tcm ( grey ), and Tem ( dark grey ) cell subsets in the blood from the non small cell lung cancer patients and healthy donors. d The events of Tn, Teff, Tcm and Tem cell subsets of CD4+ and CD8+ cells in the blood from non small cell lung cancer patients and healthy donors, expressed as the mean +- SEM. * p < 0.05; ** p < 0.005; *** p < 0.001; Mann-Whitney test (two-tailed) and non-paired Student's t-test

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1. Purity of CD3 + CD4 + CD45RA + T cells, CD3 + CD8 + T cells and CD4 + CD25 + FoxP3 + Treg cells. CD3 + CD4 + CD45RA + T cells and CD3 + CD8 + T cells were purified by magnetic cell sorting, and their purity was determined by flow cytometry. (A) The purity of CD3 + CD4 + CD45RA + T cells was 99.45% (CD3 + T cells, 99.6%; CD4 + CD45RA + T cells, 99.85%). (B) The purity of CD3 + CD8 + T cells was 95.32%. (C) The purity of CD4 + CD25 + FoxP3 + Treg cells was 93.15% (CD4 + T cells, 99.5%; CD25 + FoxP3 + T cells, 93.62%). (D) miR-155 expression in T cells of the patients with vitiligo and healthy donor was detected by reverse transcription quantitative polymerase chain reaction. **P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Non-genetic adaptation drives clinical resistance in AML. a Meta-analysis from four independent studies analysing either the whole genome or whole exome of AML patients at diagnosis and relapse. Mutations are defined as non-synonymous changes within the coding sequence of any gene. Shared mutations are mutations present at both diagnosis and relapse. Whole exome sequencing data from Li et al. (REF 4 ) was analysed to access the mutations in known AML genes, as defined by the authors. b Schematic of the treatment regime and bone marrow blast percentage for patient BET001 over the clinical trial treatment course (top panel). t-SNE analysis of 7360 individual blast cells isolated from patient BET001 at baseline, remission and relapse (bottom panel). scRNA-seq and genomic DNA sampling points are highlighted on the schematic. c Schematic of treatment regime and bone marrow blast percentage for patient BET002 over the clinical trial treatment course (top panel). t-SNE analysis of 6349 single blast cells isolated from patient BET002 at baseline and relapse (bottom panel). scRNA-seq and genomic DNA sampling points are highlighted on the schematic. d Flow cytometry analysis of cells from patient BET002 at baseline and relapse identifies enrichment for LMPP-like LSCs at relapse based on CD34 + CD38-CD90-CD45RA + expression. Gating strategy is defined by boxes. e Expression analysis of selected LSC signature genes (defined in REF 15 ) in blast cells from patient BET00